PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

I also note from the article cited in my previous post, the significance/importance of monitoring fasting blood glucose and postprandial (after eating) blood glucose. Both clinical measures were studied in a 6 month double blind placebo controlled study in which Sucanon outperformed Glyburide in reduction of fasting blood glucose and showed better results in glucose tolerance testing ( a measure of blood glucose following a specific amount of glucose ingested, designed to simulate response to a meal).
Glyburide is a common treatment for type 2 diabetes approved by FDA in the US and used worldwide.
Sucanon is approved for sale and currently available in farmacias Similares throughout Mexico, and more recently approved in Canada, and a distribution agreement in India pending further specified study (a 12 week trial in Mexico).
. Sucanon, in addition to the above, showed decreased urinary excretion of glucose than seen with Glyburide or placebo, and showed weight loss during the 6 month trial, in contrast to weight gain seen with Glyburide and other common diabetes medications. Weight loss and decreased visceral body fat were also noted in the 12 week trial in prediabetics mentioned in the previous post.